---
figid: PMC7476079__cbm-17-676-g001
figlink: pmc/articles/PMC7476079/figure/fg001/
number: F1
caption: The proposed mechanism of urokinase-type plasminogen activator receptor (uPAR)-targeted
  β-E liposomes combined with cisplatin (DDP) for the treatment of bladder cancer.
  (A) The uPAR was highly expressed in tumor cells, angiogenic endothelial cells,
  stromal fibroblasts, and macrophages. The binding of ATF24 peptide-modified liposomes
  to stromal fibroblasts, macrophages, and tumor cells enhanced the retention of liposomes
  in the tumor microenvironment and tumor tissues. Receptor-mediated internalization
  of nanoparticle drug carriers increased cellular drug delivery and therapeutic effects.
  (B) The combination of ATF24-PEG-Lipo-β-E and DDP significantly inhibited KU-19-19
  cell proliferation and promoted cell apoptosis, which were associated with the caspase-dependent
  pathway and the Cdc25C/Cdc2/cyclin B1 signaling pathway.
pmcid: PMC7476079
papertitle: An ATF24 peptide-functionalized β-elemene-nanostructured lipid carrier
  combined with cisplatin for bladder cancer treatment.
reftext: Bingtao Zhai, et al. Cancer Biol Med. 2020 Aug 15;17(3):676-692.
pmc_ranked_result_index: '3245'
pathway_score: 0.7158857
filename: cbm-17-676-g001.jpg
figtitle: Proposed mechanism of urokinase-type plasminogen activator receptor (uPAR)-targeted
  Beta-E liposomes combined with cisplatin (DDP) for the treatment of bladder cancer
year: '2020'
organisms: Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7476079__cbm-17-676-g001.html
  '@type': Dataset
  description: The proposed mechanism of urokinase-type plasminogen activator receptor
    (uPAR)-targeted β-E liposomes combined with cisplatin (DDP) for the treatment
    of bladder cancer. (A) The uPAR was highly expressed in tumor cells, angiogenic
    endothelial cells, stromal fibroblasts, and macrophages. The binding of ATF24
    peptide-modified liposomes to stromal fibroblasts, macrophages, and tumor cells
    enhanced the retention of liposomes in the tumor microenvironment and tumor tissues.
    Receptor-mediated internalization of nanoparticle drug carriers increased cellular
    drug delivery and therapeutic effects. (B) The combination of ATF24-PEG-Lipo-β-E
    and DDP significantly inhibited KU-19-19 cell proliferation and promoted cell
    apoptosis, which were associated with the caspase-dependent pathway and the Cdc25C/Cdc2/cyclin
    B1 signaling pathway.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PLAUR
  - POLD1
  - BCL2
  - BAX
  - PARP1
  - PARP2
  - PARP3
  - TIPARP
  - PARP6
  - PARP8
  - PARP10
  - PARP15
  - PARP4
  - TNKS
  - PARP14
  - PARP16
  - PARP11
  - PARP12
  - TNKS2
  - PARP9
  - Cisplatin
  - PEG
  - tumor
genes:
- word: UPAR
  symbol: UPAR
  source: hgnc_alias_symbol
  hgnc_symbol: PLAUR
  entrez: '5329'
- word: Cdc2
  symbol: CDC2
  source: hgnc_alias_symbol
  hgnc_symbol: POLD1
  entrez: '5424'
- word: Bcl-2
  symbol: Bcl-2
  source: hgnc_alias_symbol
  hgnc_symbol: BCL2
  entrez: '596'
- word: Bax
  symbol: BAX
  source: hgnc_symbol
  hgnc_symbol: BAX
  entrez: '581'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP1
  entrez: '142'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP2
  entrez: '10038'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP3
  entrez: '10039'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: TIPARP
  entrez: '25976'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP6
  entrez: '56965'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP8
  entrez: '79668'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP10
  entrez: '84875'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP15
  entrez: '165631'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP4
  entrez: '143'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: TNKS
  entrez: '8658'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP14
  entrez: '54625'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP16
  entrez: '54956'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP11
  entrez: '57097'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP12
  entrez: '64761'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: TNKS2
  entrez: '80351'
- word: PARP
  symbol: PARP
  source: bioentities_symbol
  hgnc_symbol: PARP9
  entrez: '83666'
- word: Cdc2
  symbol: CDC2
  source: hgnc_alias_symbol
  hgnc_symbol: POLD1
  entrez: '5424'
- word: UPAR
  symbol: UPAR
  source: hgnc_alias_symbol
  hgnc_symbol: PLAUR
  entrez: '5329'
chemicals:
- word: Cisplatin
  source: MESH
  identifier: D002945
- word: PEG
  source: MESH
  identifier: C499599
diseases:
- word: tumor
  source: MESH
  identifier: D009369
figid_alias: PMC7476079__F1
redirect_from: /figures/PMC7476079__F1
figtype: Figure
---
